Our data show that JM2 efficiently disrupts interaction between Cx43 and microtubules, and significantly decreases TMZ resistant GSC survival in vitro, and GSC-derived and GBM patient-derived xenograft tumor growth in vivo. This evidence concerns the gene GJA1 and glioblastoma.